Global capecitabine market is expected to reach 1031.47 million USD by 2022 QYRESEARCH FOCUS ON MARKET SURVEY AND RESEARCH
www.qyresearch.com
Beijing Hengzhou Bozhi International Information Consulting Web: qyresearchglobal.com | qyresearch.com TEL:+86-13660489419, Office:+86-2086655165 Media: press@qyresearch.com
Marketing: sales@qyresearch.com Facebook: @QYResearchOfficial, Twitter: @QYResearch_
Wechat Official Account: QYResearch, Weibo: 恒州博智
www.qyresearch.com
QYResearch Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
www.qyresearch.com
QYResearch The Capecitabine industry is highly concentrated, there are eight major manufactures in the world, and high-end products mainly come from North America and Western Europe. The capecitabine is expected to decreased at a CAGR of 0.25% from 1047.30 million USD in 2016 to reach 1031.47 million USD by 2022 in global market. In the world wide, major manufactures mainly are Roche, Teva and Mylan. North America is the largest consumer of Capecitabine and is expected to retain the lowerr growth rate during the next five years.
www.qyresearch.com
QYResearch China ave witnessed a major chunk of the production and consumption of Capecitabine in the Asia Pacific region. Actually, that is why manufacturers have several plants, usually close to aimed demand market. All manufactures in the world are committed to the improvement of product. These two years, some of Chinese and India manufactures can almost catch up with the world's leading technology too. Most technologies are developed by the manufacturers instead of importing from other companies.
Click to view the full report: https://www.qyresearch.com/index/detail/293965/global-capecitabine-market
www.qyresearch.com